Ensysce Biosciences, Inc.
As of Oct 22, 2026, Ensysce Biosciences is in Stage 1, the basing phase, now in week 10 (since Aug 13, 2026). It closed at $0.51, 77.1% below its 52-week high and above its 200-day average, which is falling.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ENSC early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ENSC among Biotechnology460th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …460 | ENSC | Stage 1 · wk 10 | 12 | +23.1% |
Ensysce Biosciences: quick answers
What stage is Ensysce Biosciences in?
As of Oct 22, 2026, Ensysce Biosciences (ENSC) is in Stage 1, the basing phase. It entered Stage 1 on Aug 13, 2026 and is in week 10. What the four stages mean
Is Ensysce Biosciences in an uptrend?
Not yet. Ensysce Biosciences is in Stage 1, a base that can come before an uptrend. It trades 14.0% above its 200-day average, which is falling.
How far is Ensysce Biosciences from its 52-week high?
Ensysce Biosciences closed at $0.51 on Oct 22, 2026, 77.1% below its 52-week high of $2.23. Its 52-week low is $0.25.
How has Ensysce Biosciences performed over the past year?
As of Oct 22, 2026, Ensysce Biosciences is down 78.0% over the past year and down 45.6% so far in 2026.
Which sector and industry is Ensysce Biosciences in?
Ensysce Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.